Exelixis Application Accepted for Neuroendocrine Tumor Candidate

 The FDA assigned a Prescription Drug User Fee Act target action date of April 3, 2025 –

– Application is based on results from the phase 3 CABINET pivotal trial, in which cabozantinib provided a statistically significant and clinically meaningful improvement in progression-free survival versus placebo –

https://www.businesswire.com/news/home/20240805262570/en